Lucitanib strongly inhibits FGFR1, FGFR2, and VEGFR1–3, and it has antiangiogenic and broad‐spectrum antitumor activity against several cancers, including small cell lung cancer, breast cancer, nasopharyngeal carcinoma, colorectal cancer, ovarian cancer, and kidney cancer.336, 337. The gene discussed is FGFR2; the disease is colorectal cancer.